Radboud University Nijmegen Medical Center, Department of Urology (659), PO Box 9101, 6500 HB Nijmegen, The Netherlands.
Bladder cancer comprises a heterogeneous group of tumors, the majority of which are non-muscle-invasive bladder cancer (NMIBC) at initial presentation. Low-risk bladder cancer--defined as pTa low-grade papillary tumors--is the type of NMIBC with the most favorable oncologic outcome. Although the risk of progression is less than 1% in 5 years, almost 15% will recur after 1 year, and 32% after 5 years. A complete transurethral resection, followed by an immediate single postoperative instillation of chemotherapy will reduce the risk of recurrence for the first 2 years. Follow-up cystoscopy is required to detect recurrence; in the vast majority of cases the recurrent tumor is of the same stage and grade as the primary tumor. The first follow-up visit, 3 months after surgery, is the most important in predicting risk of recurrence for the future. Recent developments in profiling urine and cancer tissue make it possible to better predict risk of progression and recurrence. In the future this profiling will play an important role in the timing and the choice of treatment, as well as guiding follow-up procedures.
Written by:
Falke J, Witjes JA.
Are you the author?
Reference: Nat Rev Urol. 2011 Jan;8(1):42-9.
doi: 10.1038/nrurol.2010.208
PubMed Abstract
PMID: 21228821
UroToday.com Bladder Cancer Section
